Pharmacovigilance language support

Adverse Event Translation & Safety Documentation

Translation of adverse event narratives, case-related documents and safety communications for clinical and pharmaceutical teams. Discuss the language requirements, project context and review workflow before receiving a tailored quote.

Request a Translation Quote →Explore Documents

Safety document translation

Language support for adverse event documentation

Safety teams work with source text containing medical descriptions, dates, case chronology and correspondence. The translation brief should reflect the audience and required use without adding clinical interpretation.

01 / NARRATIVES

Adverse event narratives

Source narratives and follow-up text describing suspected reactions, outcomes, dates and medical observations.

02 / CASES

Case source documents

Correspondence, statements and case-related records used within approved safety workflows.

03 / TRIALS

Clinical trial safety content

Safety notices, investigator and site communications, and study-related safety materials.

04 / FOLLOW-UP

Follow-up correspondence

Requests for information, translated replies and clarifications from relevant stakeholders.

05 / PHARMA

Pharmaceutical safety materials

Medical product safety information, notices and selected pharmacovigilance-related documentation.

06 / TERMS

Terminology review

Source-to-target terminology checking and consistency across versions when included in the scope.

Patient research transcription and escalation

Patient interviews: agree the adverse-event escalation brief before transcription

For patient or healthcare professional research interviews where an adverse event (AE), product complaint (PC) or special reporting situation (SRS) may be mentioned, Locate Translate can scope source-language transcription and, where needed, transcript translation against your client-supplied instructions. Agree how possible mentions will be flagged and handed over before work begins: a transcript alone is not a pharmacovigilance reporting service.

01 / INSTRUCTIONS

Define the escalation route

Provide the written AE/PC/SRS protocol, named safety contact and back-up, reference medicines or device terms, report template, time-zone cut-offs and agreed handover route. Confirm who monitors mentions while interviews are conducted, before transcription starts.

02 / SOURCE FIDELITY

Preserve drug names and context

Agree verbatim conventions, source-language and translated outputs, speaker labels, timestamps and uncertainty markers. Do not silently correct an unclear medicine name or infer a diagnosis; escalate terminology questions through the agreed route.

03 / PRIVACY

Separate redaction from safety evidence

Agree participant consent notices, secure transfer, access limits and a redaction specification. Remove identifiers from research deliverables as instructed, but do not erase information required for an authorised safety handover; keep any identifying information in the agreed restricted channel.

04 / QUALITY & OWNERSHIP

Record the handover and QA

Agree a check of flagged excerpts against source audio, reference terms and timestamps, with a query, revision and handover log. The commissioning research and pharmacovigilance teams determine reportability, follow-up, regulatory submissions and reconciliation under their responsibilities.

The BHBIA/ABPI market research guidance and BHBIA FAQs describe forwarding identified AE/PC/SRS information within one business day of first awareness in the relevant commissioned research workflow. This is distinct from the normal transcript deadline: agree monitoring, escalation timing and capacity explicitly. Sensitive health information also requires appropriate instructions and safeguards; see the ICO's special-category-data guidance.

For a tailored quote, describe languages, interview count and recording minutes, audio quality, participant numbers, terminology lists, redaction and timestamp requirements, secure handling, required source/translated transcripts and any separately agreed flagging or quality review. Do not send patient identifiers in the public enquiry form. Live interpreting, translation, transcription and any certification are separately scoped services; see our market research language services, or request a project quote.

Five-language oncology comments: preserve the original evidence

For an oncology study collecting written participant comments across five languages, commission a small de-identified sample and agree the output structure before translating the full dataset. Keep each source comment beside its translation into the agreed analysis language, with stable study/response IDs, source language, question code, original response order and a version field. Store any restricted participant identity key separately from the research deliverable.

Drug names and possible safety mentions: provide the client-approved brand, generic or study-product names and an oncology terminology list. Check names, negation, doses, timing and uncertainty against the source without silently correcting an unclear product or interpreting a symptom clinically. Use a separately traceable flag with source wording, response ID and a query/handover record for a possible AE, product complaint or special reporting situation. Agree who monitors written comments from first access and follows the client-supplied escalation timings; do not wait for the completed translation batch. The research sponsor and pharmacovigilance team retain reportability and submission decisions.

Quality and quotation brief: specify all language pairs, comment/word volumes, editable Excel or CSV file, column map, glossary, redaction rules, restricted-access transfer, bilingual sample/checking plan, issue log, responsible reviewer and delivery stages. Agree the safety handover and final dataset approval separately. Written comment translation does not automatically include audio transcription, live interpreting, questionnaire linguistic validation, desktop publishing or certified translation. Availability, price and turnaround require project review; do not include identifiable patient information in the public enquiry form.

Live multilingual interviews: briefing interpreters to flag possible safety mentions

Yes, with an agreed project brief. Multilingual interview interpreters can be instructed to discreetly flag a possible adverse event (AE), product complaint (PC) or special reporting situation (SRS) to the moderator or designated safety contact. Their job is faithful interpreting and routing possible mentions, not diagnosing, assessing causality or deciding reportability. Confirm the roles and escalation route before the interview.

1. Prepare the briefing: the research team supplies the written client AE/PC/SRS procedure, approved participant/consent wording, brand/generic/study-product and device terms, language and dialect, moderator’s guide, primary and back-up safety contacts, discreet alert channel, first-awareness handover rules, time-zone cut-offs and data restrictions. Agree who monitors live mentions and whether interpreter flagging, training evidence and handover records are included in the booked scope; do not assume availability or prior PV training.

2. Flag without clinical judgement: interpret the speaker’s words accurately, preserving timing, uncertainty, negation and unclear drug names. Discreetly signal a potential mention via the agreed channel, preserving source-language wording and the session/time reference where allowed. Do not independently probe, make a medical assessment or delay alerting until the transcript is ready. The moderator or researcher decides how to handle participant questions and follow-up using the client-approved process.

3. Protect the evidence: follow the project’s confidentiality, recording, access and redaction instructions. Keep ordinary research outputs de-identified where specified, but transfer safety-relevant details only to authorised contacts through an approved restricted channel. Agree a minimal QA and handover log: interview reference, exact phrase, language, timestamp, product term or uncertainty, recipient, time sent, acknowledgement and corrections; source-audio checks are possible only if recordings and review are in scope.

4. Confirm ownership and pricing: BHBIA/ABPI guidance addresses market research agency and subcontractor first-awareness handling, including forwarding identified AE/PC/SRS information within one business day where applicable. The research and pharmacovigilance teams determine reportability, assessment, reconciliation and regulatory submissions; an interpreter is not the PV decision-maker. For a quote, provide session dates/duration, interpreting mode and platform, languages/dialects, guide, reference terms, client escalation/consent protocol, security and QA/logging needs. Live interpreting, later transcription, written translation, certification, desktop publishing and localisation are separate deliverables; capacity, training checks, deadlines and price require confirmation. See the BHBIA/ABPI guidance, our market research services and project enquiry; do not put patient identifiers in the public form.

Vulnerable research participants: redaction and confidentiality checklist

Direct answer: For interviews involving vulnerable people or sensitive health information, agree what the language team may see, what must be redacted and how possible adverse-event (AE) mentions reach an authorised safety contact before sharing identifiable files. Ask for a de-identified sample for quotation; do not place patient details in a public enquiry.

1. Set the data-protection brief. The commissioning controller/research team should document the purpose, its UK GDPR Article 6 lawful basis and any required Article 9 health-data condition, participant information and the roles of suppliers. Assess indirect identifiers such as rare diagnoses, locations and recognisable voices, as well as names. Confirm whether a data protection impact assessment (DPIA) is needed because the processing is likely to be high risk, including heightened participant vulnerability; do not treat research consent alone as proof of a lawful processing basis.

2. Prepare restricted files and instructions. Supply approved participant/study reference IDs, an interview guide, client-approved drug and device terms, a written redaction matrix (names, contact details, third-party mentions and indirect identifiers) and a separately restricted identity key only where necessary. Agree secure transfer, permitted recipients, confidentiality duties, approved sub-processors, storage location, retention/deletion and incident escalation in the relevant controller–processor arrangements. Pseudonymised data can still be personal data.

3. Keep research redaction separate from safety escalation. Deliver de-identified transcripts or translations as specified, without changing clinical wording, product names, negation, timing or uncertainty. If the client's AE/PC/SRS protocol calls for identifiable information to be escalated, use its named primary/back-up safety contact and restricted handover channel; do not expose those details in the general research deliverable. The research sponsor and pharmacovigilance team decide reportability and follow-up, not the translator or transcriber.

4. Check and price the actual scope. Agree source-audio versus transcript redaction, who verifies removed identifiers and retained safety context, any bilingual checks, study IDs, timestamps, restricted-query and handover logs, reviewer approvals and acceptance criteria. For a tailored quote, specify language pairs, recording minutes or word count, file types, redaction rules, approved access, deadline and whether source-language transcription, written translation, live interpreting or optional certification, DTP and localisation are needed separately. Security arrangements, capacity, fees and timings must be confirmed for the project.

Primary guidance: ICO special-category health data, pseudonymisation and processor contracts. For interview delivery options, see market research language services or discuss a scoped quote.

Rolling medical interview batches: turnaround, safety flags and QA evidence

What to request: Treat each incoming interview batch as a tracked deliverable with agreed receipt cut-offs, acknowledgement, estimated transcription or translation and reviewer windows, correction cycles and acceptance criteria. Agree an initial sample, realistic buffers for late recordings, poor audio or terminology queries and a staged schedule based on language pairs, recording minutes and actual review scope, rather than assuming a guaranteed same-day turnaround.

1. Prepare a controlled intake. Provide de-identified interview IDs, recording durations, source languages or dialects, file formats, speaker and timestamp conventions, approved drug or device glossary, secure transfer arrangements and client-approved consent/redaction instructions. Ask for a batch register documenting receipt, version, allocation, queries, review, delivery and corrections. Define how replacement audio or extra interviews change the milestones.

2. Keep potential safety mentions on their own clock. Supply the commissioning team's written AE/PC/SRS escalation protocol, named primary and back-up safety contacts, authorised restricted transfer route, template and time-zone cut-offs. Specify who monitors live interviews and newly available files, what constitutes first awareness under the client's SOP, and how a possible mention is flagged without waiting for the final transcript. The BHBIA market-research FAQs describe forwarding identified AE/PC/SRS information within one business day of first awareness where applicable. Translators or transcribers flag and route possible mentions; research/sponsor/pharmacovigilance teams determine reportability, reconciliation and regulatory submissions.

3. Request QA evidence batch by batch. Agree source-audio spot checks, bilingual checking where commissioned, client reference-term verification, unresolved wording or negation queries, redaction checks, reviewer approvals, source/target version IDs and a correction/acceptance register. Request a timestamped restricted safety-handover record with recipient and acknowledgement, kept separately from de-identified research transcripts. Agree what records may be retained, by whom and for how long, under the project's confidentiality and data-processing instructions.

Quote and scope: Provide approximate recording minutes and arrival cadence per language, source and desired output formats, client protocol, terminology list, redaction and access rules, QA/review requirements, delivery checkpoints and any final reconciliation window. Transcription, written translation, live interpreting, certification, desktop publishing and localisation are separate deliverables; request an itemised staged quotation and confirmed capacity before setting contractual deadlines. For related services see market research language support or request a scoped quote without patient identifiers.

Responsibilities and reporting

Translation is not regulatory adverse event reporting

This page is for translation requests, not for submitting actual adverse event reports. Locate Translate does not act as the regulator or take over a sponsor's or marketing authorisation holder's reporting responsibilities through a translation enquiry.

Case assessment, coding, validation, reporting and submission obligations remain with the relevant responsible organisation. A translation must fit into that organisation's pharmacovigilance workflow.

To report a suspected reaction or medical-device concern in the UK, use the appropriate official MHRA Yellow Card channel.

Discuss Translation Support →

Document the source and intended audience
Preserve chronology and original source meaning
Identify relevant medicines, doses and terminology
Agree review and sign-off responsibilities
Keep reporting deadlines with the responsible organisation

Pharmacovigilance context

Case terminology, traceability and source accuracy

Adverse event narratives may contain medical abbreviations, dates, medication histories and ambiguous wording. Translation should reflect the source rather than introduce unsupported clinical conclusions.

For ICSR-related documents, clarify approved terminology, source version, data-handling requirements and review responsibilities. Coding decisions, causality assessments and submission obligations are separate from translation.

EU guidance discusses verbatim source text, accurate translations and confidentiality in safety reporting. See EMA GVP Module VI.

Medical terminology and abbreviations
Drug names, quantities and timelines
Legible source information and uncertainty flags
Terminology consistency across follow-ups
Appropriate review and version handling

PV procurement: evidence to request from a safety-narrative translation supplier

For translated adverse-event case narratives and follow-up documents, request a project-specific evidence pack: a redacted source-and-translation sample, agreed responsibilities, a written quality-check plan and a retrievable handover record. This is supplier due diligence, not evidence that any language agency is regulator-approved.

1. Instructions and accountability. Ask for a scope and responsibility matrix distinguishing translation and linguistic checking from case assessment, MedDRA coding, causality, ICSR validation, regulatory submission and follow-up, which remain with the commissioning pharmacovigilance organisation. Supply your AE/PC/SRS escalation procedure, named primary and back-up safety contacts, first-awareness handover rules, cut-offs and exceptional-case route. Ask the supplier to show how receipt, queries and flagged possible safety mentions would be passed to your team; do not assume the completed translation deadline meets an earlier escalation deadline.

2. Source fidelity and checking. Provide approved brand, generic and study-product terms plus any client terminology and style rules. Request a bilingual review plan covering product names, doses and units, dates, chronology, negation, uncertainty and follow-up changes against the original. Specify how illegible text and disputed terms are queried rather than silently corrected; agree whether an additional medically qualified reviewer is needed and who signs off.

3. Traceable deliverables. Ask how the supplier would identify source file and version, case or document reference, language pair, corresponding translated file, reviewer role, queries, corrections, handover time and client acceptance. Agree a minimal, access-controlled issue and version log that can be retrieved for your audit or inspection process; request a sample template before appointment. Do not put identifiable patient data in a sales enquiry or general-purpose sample.

4. Confidentiality, redaction and contract evidence. Confirm secure-transfer methods, role-based access, confidentiality commitments, authorised sub-processors, storage region, retention/deletion, incident escalation and any appropriate controller–processor terms. Set a written redaction specification: de-identify routine research outputs but do not suppress safety information needed by the authorised PV recipient; keep the identity key and unrestricted handover in approved restricted channels. Agree record availability and cooperation provisions where translation forms part of an outsourced PV system.

5. Comparable quote and handover. Supply redacted representative narratives, language pairs, word counts, editable source formats, source/target version map, glossary, data-handling and review instructions, proposed escalation cut-offs, acceptance criteria and delivery stages. Request separate pricing and approval for written translation, source-audio transcription, live interpreting, certified translation, desktop publishing or system localisation where needed. Price, linguist/reviewer availability and timings are confirmed only after project review; request a scoped quote without including patient identifiers.

Relevant procurement context: EMA GVP Modules I and VI, MHRA GPvP inspection guidance and ICO controller–processor contracts guidance. The commissioning sponsor/marketing authorisation holder determines its applicable PV and data-protection requirements.

A defined language workflow

How to arrange adverse event translation

Agree confidentiality and secure transfer before providing any identifiable patient details.

01 / BRIEF

Describe the project

Explain document types, languages, volume and intended use.

02 / SCOPE

Agree the review plan

Confirm terminology, delivery stages and output requirements.

03 / TRANSLATE

Prepare translations

Work from agreed source documents and context information.

04 / HANDOVER

Deliver agreed files

Return output for the relevant organisation's onward safety process.

Secure files and urgent timings

Quote a project without exposing sensitive case data

Pharmacovigilance records can contain patient and reporter identifiers. Do not enter individual case details in the public quote form. First discuss secure transfer and confidentiality requirements.

Translation price and timeframe depend on language pair, medical complexity, document volume, file format, required checking and priority. Regulatory reporting deadlines remain with the responsible organisation.

Document inventory and target languages
Source formats and required outputs
Approved glossary and terminology
Review and checking stages
Secure file-sharing requirements
Translation milestones and deadline

Related services

Medical and life sciences language support

Other medical, research and clinical language requirements have their own specialist pages.

Frequently asked questions

Adverse Event Translation FAQs

Understand what can be translated and how this differs from regulatory safety reporting.

Ask About Your Project →

What is adverse event translation?

It is the translation of safety narratives, related case materials, follow-up correspondence and other content used in pharmacovigilance or clinical research workflows.

Does this service submit adverse event reports to MHRA or EMA?

No. This is a language-service enquiry, not an adverse event intake or regulatory submission channel. Reports should be handled by the appropriate authority or organisation.

Can you translate ICSR source narratives?

You can enquire about translation of ICSR-related source material and case narratives. Share the project requirements without including patient identifiers in the public form.

Do you translate safety follow-up communications?

We can review requests for follow-up text, case correspondence and supporting documents with agreed language and review requirements.

Does translation include medical coding or causality assessment?

No. Coding, case validation, causality assessment and clinical judgement are distinct responsibilities and not included automatically in translation.

How should confidential case information be shared?

Discuss approved secure file transfer and contractual requirements before supplying case-specific sensitive or identifiable records.

Can urgent safety-related content be translated?

An urgent translation requirement can be discussed, but the timetable depends on language, volume and review. Relevant regulatory reporting deadlines remain with the responsible organisation.

What determines the cost of adverse event translation?

Pricing depends on volume, languages, medical terminology, source format, checking and deadline. Provide a high-level project summary for a tailored quotation.

Project enquiries

Discuss your adverse event translation requirements

Share languages, document types and desired turnaround. We can scope language support without taking in adverse event reports through this page.

Request a Quote →Contact Us

Request an Adverse Event Translation Quote

Describe the languages, document types and deadline only. Do not submit identifiable patient details or actual adverse event reports through this form. Please arrange secure transfer first.